472 related articles for article (PubMed ID: 24937379)
1. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
2. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
3. Application of Central Composite Design in Optimization of Valsartan Nanosuspension to Enhance its Solubility and Stability.
Vuppalapati L; Cherukuri S; Neeli V; Yeragamreddy PR; Kesavan BR
Curr Drug Deliv; 2016; 13(1):143-57. PubMed ID: 26205900
[TBL] [Abstract][Full Text] [Related]
4. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
5. Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.
Li Z; Zhang W; Gao Y; Xiang R; Liu Y; Hu M; Zhou M; Liu X; Wang Y; He Z; Sun Y; Sun J
Drug Deliv Transl Res; 2017 Feb; 7(1):100-110. PubMed ID: 27812915
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of paclitaxel nanosuspension using novel emulsification method by combining high speed homogenizer and high pressure homogenization.
Li Y; Zhao X; Zu Y; Zhang Y
Int J Pharm; 2015 Jul; 490(1-2):324-33. PubMed ID: 26027492
[TBL] [Abstract][Full Text] [Related]
7. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
Biswas N
Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
9. Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization.
Prieto C; Evtoski Z; Pardo-Figuerez M; Hrakovsky J; Lagaron JM
Mol Pharm; 2021 Aug; 18(8):2947-2958. PubMed ID: 34181413
[TBL] [Abstract][Full Text] [Related]
10. Rutin nanosuspension for potential management of osteoporosis: effect of particle size reduction on oral bioavailability,
Gera S; Pooladanda V; Godugu C; Swamy Challa V; Wankar J; Dodoala S; Sampathi S
Pharm Dev Technol; 2020 Oct; 25(8):971-988. PubMed ID: 32403972
[TBL] [Abstract][Full Text] [Related]
11. Enhanced dissolution and oral bioavailability of valsartan solid dispersions prepared by a freeze-drying technique using hydrophilic polymers.
Xu WJ; Xie HJ; Cao QR; Shi LL; Cao Y; Zhu XY; Cui JH
Drug Deliv; 2016; 23(1):41-8. PubMed ID: 24735247
[TBL] [Abstract][Full Text] [Related]
12. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
13. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
14. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
15. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
16. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
17. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
Chella N; Daravath B; Kumar D; Tadikonda RR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
[TBL] [Abstract][Full Text] [Related]
18. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
19. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
[TBL] [Abstract][Full Text] [Related]
20. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]